CRO Clinipace, which has pulled the trigger on 5 acquisitions in as many years, raised $50 million in debt and equity to bankroll the next phase of its expansion effort.
North Carolina CRO Clinipace has raised $4 million, and while the company isn't disclosing why it needs the cash, the move follows years of dealmaking and could be a prelude to another buyout.
Clinipace has signed a far-reaching deal with biotech Karyopharm, agreeing to handle a host of studies under a preferred provider arrangement.
Global CRO Clinipace has agreed to manage clinical trials for Nexstim as the Finnish devicemaker works toward FDA approval for its neurostimulation therapy.
North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.
Clinipace has struck a deal with Finland's Medfiles, allowing the North Carolina CRO to offer its clients services across the Nordics and Baltic countries.
Clinipace has revamped its eClinical data platform, TEMPO, saying its new offering rolls disparate IT applications into one, allowing clients to cut down the cost and complexity of their clinical trials.
A month after doubling in size with its buyout of Paragon Biomedical, Clinipace has raised $9 million to flesh out its workforce.
Clinipace has struck a deal to acquire California's Paragon Biomedical, a move the CRO says will boost its therapeutic expertise and expand its footprint around the world.
CRO Clinipace is providing electronic data capture, clinical monitoring, site management, biostatistical consulting and regulatory document management for Inspire Pharmaceuticals for Phase 2 clinical